

# Shi-Chun Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8749945/publications.pdf>

Version: 2024-02-01

45  
papers

1,316  
citations

516710

16  
h-index

377865

34  
g-index

55  
all docs

55  
docs citations

55  
times ranked

2068  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Hepatocytes with Drug Metabolic Function Induced from Fibroblasts by Lineage Reprogramming. <i>Cell Stem Cell</i> , 2014, 14, 394-403.	11.1	279
2	Long-term functional maintenance of primary human hepatocytes in vitro. <i>Science</i> , 2019, 364, 399-402.	12.6	147
3	Chemical reprogramming of human somatic cells to pluripotent stem cells. <i>Nature</i> , 2022, 605, 325-331.	27.8	144
4	S100A4 promotes liver fibrosis via activation of hepatic stellate cells. <i>Journal of Hepatology</i> , 2015, 62, 156-164.	3.7	133
5	Promotion of the efficient metabolic maturation of human pluripotent stem cell-derived hepatocytes by correcting specification defects. <i>Cell Research</i> , 2013, 23, 157-161.	12.0	47
6	A Single-institution Experience with Open Irreversible Electroporation for Locally Advanced Pancreatic Carcinoma. <i>Chinese Medical Journal</i> , 2016, 129, 2920-2925.	2.3	46
7	Laparoscopic anatomical liver resection guided by real-time indocyanine green fluorescence imaging: experience and lessons learned from the initial series in a single center. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 4683-4691.	2.4	45
8	Hepatic spheroids derived from human induced pluripotent stem cells in bio-artificial liver rescue porcine acute liver failure. <i>Cell Research</i> , 2020, 30, 95-97.	12.0	44
9	A two-step lineage reprogramming strategy to generate functionally competent human hepatocytes from fibroblasts. <i>Cell Research</i> , 2019, 29, 696-710.	12.0	43
10	miRNA-346 promotes proliferation, migration and invasion in liver cancer. <i>Oncology Letters</i> , 2017, 14, 3255-3260.	1.8	33
11	Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade. , 2019, 7, 125.		32
12	Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition). <i>Liver Cancer</i> , 2022, 11, 315-328.	7.7	31
13	Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2013, 85, 219-227.	5.0	30
14	Nuclear EGFR impairs ASPP2-p53 complex-induced apoptosis by inducing SOS1 expression in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 16507-16516.	1.8	29
15	Generation of human hepatocytes from extended pluripotent stem cells. <i>Cell Research</i> , 2020, 30, 810-813.	12.0	22
16	Risk factors of delayed gastric emptying following pancreaticoduodenectomy. <i>ANZ Journal of Surgery</i> , 2016, 86, 69-73.	0.7	21
17	Construction and Validation of a Ferroptosis-Related lncRNA Signature as a Novel Biomarker for Prognosis, Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 792676.	3.7	18
18	Diagnosis and treatment of cholangiocarcinoma: A consensus from surgical specialists of China. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2014, 34, 469-475.	1.0	17

#	ARTICLE	IF	CITATIONS
19	Abnormal splenic artery diameter/hepatic artery diameter ratio in cirrhosis-induced portal hypertension. <i>World Journal of Gastroenterology</i> , 2013, 19, 1292.	3.3	17
20	Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review. <i>BioScience Trends</i> , 2022, 16, 130-141.	3.4	14
21	Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13945-56.	0.5	13
22	Indocyanine green fluorescence image-guided total laparoscopic living donor right hepatectomy: The first case report from Mainland China. <i>International Journal of Surgery Case Reports</i> , 2018, 53, 406-409.	0.6	11
23	Analysis of delayed discharge after day-surgery laparoscopic cholecystectomy. <i>International Journal of Surgery</i> , 2017, 40, 33-37.	2.7	10
24	Reestablishment of Active Immunity against HBV Graft Reinfection after Liver Transplantation for HBV-Related End Stage Liver Disease. <i>Journal of Immunology Research</i> , 2014, 2014, 1-9.	2.2	9
25	Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 744571.	4.8	8
26	Perioperative and long-term outcomes of liver resection for hepatitis B virus-related hepatocellular carcinoma without versus with hepatic inflow occlusion: study protocol for a prospective randomized controlled trial. <i>Trials</i> , 2016, 17, 492.	1.6	7
27	The Effect of Splenectomy on the Reversal of Cirrhosis: a Prospective Study. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-10.	1.5	7
28	PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: An open-label, non-randomized, phase IV study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16173-e16173.	1.6	7
29	Long-term consequences of stopping HBIG and/or nucleotide analogues in liver transplant recipients administered hepatitis B vaccination to prevent HBV reinfection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 85-89.	2.0	6
30	The detection of (total and ccc) HBV DNA in liver transplant recipients with hepatitis B vaccine against HBV reinfection. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2490-2494.	3.3	5
31	Usefulness of three-dimensional visualization technology in minimally invasive treatment for infected necrotizing pancreatitis. <i>World Journal of Gastroenterology</i> , 2018, 24, 1911-1918.	3.3	5
32	Efficacy and safety of a reduced calcineurin inhibitor dose combined with mycophenolate mofetil in liver transplant patients with chronic renal dysfunction. <i>Oncotarget</i> , 2017, 8, 57505-57515.	1.8	5
33	Short-term effects of splenectomy on serum fibrosis indexes in liver cirrhosis patients. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 15260-4.	0.5	5
34	Surgeons' response to COVID-19: modified workflow to adapt to the new normal. <i>British Journal of Surgery</i> , 2020, 107, e318-e319.	0.3	4
35	Nomograms Predicting the Occurrence of Sepsis in Patients following Major Hepatobiliary and Pancreatic Surgery. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-10.	1.5	3
36	Postoperative inflammation as a possible cause of portal vein thrombosis after irreversible electroporation for locally advanced pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2017, 23, 6003.	3.3	3

#	ARTICLE	IF	CITATIONS
37	Expert consensus on organizing the multidisciplinary team (MDT) diagnosis and treatment of hepato-pancreato-biliary diseases in China. <i>Science China Life Sciences</i> , 2022, 65, 1036-1039.	4.9	3
38	Regorafenib Combined With Sirolimus Achieves Successful Treatment of Diffuse Double Lung Metastasis After Liver Transplantation in Giant Liver Cancer Beyond Transplantation Criteria: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 634-637.	0.6	2
39	Retrospective observation of therapeutic effects of adult auxiliary partial living donor liver transplantation on postpartum acute liver failure: A case report. <i>World Journal of Gastroenterology</i> , 2015, 21, 2840.	3.3	2
40	Safety of ambulatory laparoscopic cholecystectomy in the elderly. <i>ANZ Journal of Surgery</i> , 2021, 91, 597-602.	0.7	1
41	Splenectomy with Portoazygous Disconnection for Correction of Systemic Hemodynamic Disorders in Hepatic Cirrhosis Patients with Portal Hypertension: A Prospective Single-Center Cohort Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-6.	1.9	1
42	Hepatitis B Virus Pregenomic RNA Reflecting Viral Replication in Distal Non-tumor Tissues as a Determinant of the Stemness and Recurrence of Hepatocellular Carcinoma. <i>Frontiers in Microbiology</i> , 2022, 13, 830741.	3.5	1
43	An immune response-associated genomic model to predict early resistance to PD1/PD-L1 blockade among real-world TMB-high Chinese cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14167-e14167.	1.6	0
44	Significance of incorporation of DNMT1 and HLA-DRÎ± with TNM staging in patients with hepatocellular carcinoma after curative resection. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 9372-9381.	0.5	0
45	The value of pretreatment <sup>18</sup> F-FDG PET/CT to predict the pathological treatment response of hepatocellular carcinoma patients treated with PD-1 inhibitors and lenvatinib as a conversion therapy in BCLC stage C.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16130-e16130.	1.6	0